The very best clinical practice does not take place in a vacuum.
It requires input and expertise from many groups: clinicians; patient organisations; academics; healthcare organisations; and the manufacturers of new medicines and medical technology. Collaboration between my industry and these important customers results in three main benefits:
1. Making new medicines possible in the first place;
2. Providing vital health education needed to ensure that medicines are used appropriately; and
3. Capturing patient insights into current treatments and understanding unmet medical needs.
The adoption of the EFPIA Healthcare Professional (HCP)/Healthcare Organisation (HCO) Disclosure Code will deliver long awaited financial transparency around these collaborations. More importantly, it will be a positive force, serving to demonstrate that the over-riding objective is to keep the patient at the centre of our collective work.
To read the article by Tim McGuire, Director Global Transparency at Eli Lilly
